Browse the evidence

Weight gain occurring between age 30 years and menopause is associated with a greater increase in breast cancer risk than weight gain occurring between age 18 and 30 years, although the difference in risk magnitude between these two periods is not statistically significant.

While gaining weight between ages 18 and 30 is less risky than gaining weight after 30, both increase risk compared to staying thin. However, if you gained weight in your 20s, you are not doomed; losing that weight in your 30s or after menopause brings your risk down to levels similar to women who never gained weight. Prioritize preventing weight gain after age 30, but know that correcting it later is highly effective.

High cumulative inflammatory load, specifically the combination of elevated Interleukin-6 (IL-6) and Tumor Necrosis Factor-alpha (TNF-α), is associated with significantly increased odds of short leukocyte telomere length (LTL) in older adults.

In older adults, high levels of specific inflammatory cytokines (IL-6 and TNF-α) are linked to shorter telomeres, a marker of biological aging. Standard CRP tests may not capture this risk. Managing chronic inflammation through lifestyle factors (diet, exercise, stress reduction) may help preserve telomere length, although this study is observational and does not prove causation.

Peripheral administration of long-acting GLP-1 receptor agonists (liraglutide and exendin-4) suppresses food intake and body weight through a combined mechanism involving both direct activation of central nervous system (CNS) GLP-1 receptors and activation of peripheral vagal afferent GLP-1 receptors.

Long-acting GLP-1 medications (like liraglutide) reduce appetite not just by signaling the stomach, but by also acting directly on the brain. This dual action is key to their effectiveness. If one pathway is blocked or less sensitive, higher doses may be needed to achieve the same result.

Insulin resistance (IR) is the primary mechanistic link connecting Metabolic Syndrome (MetS) to increased risk of Alzheimer's Disease (AD) and cognitive impairment, driven by impaired PI3K-Akt signaling, increased amyloid-beta (Aβ) production, and tau hyperphosphorylation.

Maintain metabolic health to protect your brain. If you have metabolic syndrome, obesity, or type 2 diabetes, your risk for cognitive decline is significantly higher due to insulin resistance. Prioritize interventions that improve insulin sensitivity (like exercise and diet) as they may directly protect against Alzheimer's pathology by preserving brain insulin signaling.

In the presence of a high-fat diet, fructose supplementation causes pronounced obesity, glucose intolerance, and hepatic insulin resistance, whereas glucose supplementation does not cause these metabolic deficits despite similar caloric intake.

If you are eating a high-fat diet, the type of sugar you consume matters significantly. Fructose (found in high-fructose corn syrup and table sugar) promotes obesity and insulin resistance, whereas glucose does not have the same negative impact on insulin signaling under these conditions. To mitigate metabolic risk, prioritize reducing fructose intake, especially when dietary fat is high.

Fructose uniquely upregulates the transcription factor SREBP1c and downstream fatty acid synthesis genes, leading to reduced liver insulin signaling, whereas glucose upregulates ChREBP and triglyceride synthesis without impairing insulin signaling.

Understanding how different sugars affect your liver can help you make better choices. Fructose drives fat production and insulin resistance through specific genetic pathways (SREBP1c), while glucose may actually support insulin sensitivity. If you consume high-fat meals, minimizing fructose (soda, candy) is more critical for metabolic health than avoiding glucose sources.

Roux-en-Y gastric bypass (RYGBP) surgery induces an exaggerated postprandial secretion of Peptide YY (PYY) and suppresses fasting bioactive (octanoylated) ghrelin levels, mechanisms that contribute to sustained weight loss and maintenance by promoting early satiety and reducing hunger.

For individuals with morbid obesity, Roux-en-Y gastric bypass surgery alters gut hormones to favor weight loss maintenance. Specifically, it triggers a strong release of Peptide YY (PYY) after eating, which signals fullness to the brain, and lowers active ghrelin (the hunger hormone). This hormonal shift helps patients feel full sooner and stay full longer, making it easier to maintain weight loss compared to dieting alone.

Unlike diet-induced weight loss, Roux-en-Y gastric bypass (RYGBP) does not trigger a compensatory increase in fasting ghrelin levels, thereby avoiding the hormonal drive for hunger typically associated with caloric restriction.

When you lose weight through dieting, your body naturally increases hunger hormones (ghrelin) to make you eat more. Roux-en-Y gastric bypass surgery avoids this biological backlash. Patients maintain lower levels of active ghrelin, meaning they do not experience the intense hunger spikes that often cause diet failures, making long-term weight maintenance easier.

Mitochondrial dysfunction, characterized by impaired oxidative capacity and increased reactive oxygen species (ROS), promotes insulin resistance in skeletal muscle by causing the accumulation of lipotoxic lipid intermediates (diacylglycerol and ceramide) that inhibit insulin signaling.

For those with insulin resistance or T2DM, focusing on interventions that support mitochondrial health (like exercise which upregulates PGC-1α) may be more effective than focusing solely on caloric restriction. The paper suggests that boosting mitochondrial function can improve insulin sensitivity, potentially by reducing toxic lipid buildup in muscles.

Obesity-induced adipose tissue hypertrophy triggers a proinflammatory state (via TNF-α, IL-6, MCP-1, and reduced adiponectin) that directly causes endothelial dysfunction by disrupting the balance of vasodilators (NO) and vasoconstrictors, initiating atherosclerosis and cardiovascular disease.

Excess body fat is not just stored energy; it acts as an active organ that releases inflammatory chemicals (like TNF-α and IL-6) and reduces protective ones (adiponectin). This chemical imbalance damages the inner lining of your blood vessels (endothelium), leading to stiffness, plaque buildup, and heart disease risk. Managing weight and inflammation is critical to protecting your vascular health.

Fetal exposure to nutrient restriction programs a 'thrifty phenotype' that increases susceptibility to type 2 diabetes and cardiovascular disease when the individual encounters an environment of nutritional abundance.

If you were born small or in a low-resource environment, your body is biologically programmed to store energy efficiently. When you have access to abundant food, this 'thrifty' programming makes you highly susceptible to weight gain and diabetes. You must be proactive about diet and activity, as your body will fight harder to store fat than someone with a different early-life history.

Perivascular adipose tissue (PVAT) and epicardial adipose tissue (EAT) exert local paracrine effects on cardiovascular health, functioning as protective in lean states via adiponectin and prostacyclin release, but becoming pathogenic in obesity by shifting to a pro-inflammatory state that promotes vasoconstriction, smooth muscle proliferation, and atherosclerosis.

Epicardial and perivascular fat are biologically active tissues that influence heart health. In lean individuals, they release protective substances like adiponectin that keep blood vessels flexible and healthy. In obesity, these depots become inflamed, releasing harmful substances that stiffen arteries and promote plaque buildup. While imaging these fats is useful for research, current evidence suggests that overall visceral fat reduction (via weight management) is the most effective way to mitigate these risks, as local fat measurements do not significantly add to risk prediction beyond standard visceral fat metrics.

A flatter diurnal slope in salivary cortisol (characterized by elevated evening levels rather than depressed morning levels) is associated with a significantly increased risk of cardiovascular mortality in middle-aged adults.

This research suggests that how your cortisol levels drop throughout the day is more important for heart health than how high they are in the morning. Specifically, a 'flat' slope—where evening cortisol remains elevated rather than declining—predicts higher cardiovascular risk. While you cannot directly 'dose' cortisol, this pattern is often linked to chronic stress, poor sleep, or fatigue. Prioritizing stress reduction techniques and ensuring adequate sleep duration may help normalize this diurnal rhythm, potentially lowering cardiovascular risk.

The combination of GH and IGF-I attenuates the hypoglycemia caused by IGF-I alone while maintaining better glucose tolerance than GH alone.

When treating catabolism, using IGF-I alone can dangerously lower blood sugar, often requiring dose reductions. Adding Growth Hormone to the regimen stabilizes blood glucose levels, preventing these lows without causing the high blood sugar typically associated with GH alone. This balance makes the combination therapy metabolically safer and more sustainable than IGF-I monotherapy.

The combination of GH and IGF-I increases serum IGF-I concentrations and stabilizes the IGF-I pool by inducing IGFBP-3 and Acid-Labile Subunit (ALS), leading to greater anabolic efficacy.

The combination therapy works partly by increasing the amount of stable IGF-I in the blood. GH stimulates the production of binding proteins (IGFBP-3 and ALS) that protect IGF-I from rapid breakdown, allowing it to work more effectively and for longer periods than IGF-I alone.

Pharmacologic inhibition of hepatic FMO3 reduces circulating TMAO and atherosclerosis but simultaneously decreases plasma glucose, insulin, and lipids, indicating that FMO3 inhibition has broad metabolic effects beyond lipid/TMAO modulation.

Current research suggests that inhibiting the enzyme FMO3 might lower cardiovascular risk markers like TMAO and atherosclerosis, but it also significantly lowers blood sugar and insulin levels. This means that any potential therapeutic strategy targeting FMO3 must account for these broad metabolic changes, as it is not just a simple lipid or TMAO modulator. For now, this is a mechanistic finding in mice, not a human treatment protocol.

Aging is associated with an attenuated rise in muscle protein synthesis rate following the ingestion of dietary protein, a phenomenon termed anabolic inflexibility.

As you age, your muscles become less sensitive to the muscle-building signal from protein. This doesn't mean protein is useless, but it means you likely need to consume more protein per meal to get the same muscle-building effect you got when you were younger. Focus on ensuring adequate protein intake at each meal rather than just total daily volume.

In skeletal muscle, the accumulation of lipid intermediates such as diacylglycerol (DAG) and ceramides directly impairs insulin-stimulated glucose uptake by activating serine/threonine kinases that inhibit the insulin receptor substrate-1 (IRS-1).

If you have insulin resistance, simply reducing total body fat is the standard approach, but understanding that specific toxic lipid byproducts (like DAGs) are the direct cause helps explain why some lean individuals or athletes might have different metabolic profiles. Focus on improving metabolic flexibility through exercise, which helps clear these toxic intermediates.

Perilipin 2 (PLIN2) and Perilipin 5 (PLIN5) overexpression in skeletal muscle can protect against lipotoxicity and improve insulin signaling by sequestering fatty acids into lipid droplets, thereby reducing toxic lipid intermediates like DAG and ceramides.

Endurance training and metabolic health can upregulate protective proteins like PLIN5, which help store fatty acids safely in lipid droplets. This prevents them from turning into toxic byproducts that block insulin action. Prioritize exercises that improve metabolic flexibility.

Intermittent hypoxia, the hallmark of Obstructive Sleep Apnoea Syndrome (OSAS), preferentially activates inflammatory transcription factors (specifically NF-kB and AP-1) over adaptive pathways, leading to endothelial dysfunction and increased cardiovascular risk.

If you have Obstructive Sleep Apnoea, treating it with CPAP is critical for your heart health, not just your energy levels. The repeated drops in oxygen during sleep trigger inflammation that damages your blood vessels. Effective CPAP therapy has been shown to significantly reduce these inflammatory markers (like TNFa) and improve endothelial function, thereby lowering your long-term risk of heart disease and stroke.

Continuous Positive Airway Pressure (CPAP) therapy significantly reduces circulating levels of specific pro-inflammatory markers (notably TNFa and adhesion molecules) and improves endothelial function in OSAS patients.

Using CPAP consistently every night is the most effective way to lower the inflammation caused by your sleep apnea. Studies show it significantly reduces harmful markers like TNFa and helps repair your blood vessels. While it takes time to get used to the mask, the protection it offers your heart and brain is substantial.

Endothelial function, measured by flow-mediated dilation, progressively declines across the stages of the menopause transition, independent of traditional cardiovascular risk factors and age.

For women in the perimenopausal and postmenopausal stages, maintaining cardiovascular health requires extra attention to vascular markers like blood pressure and cholesterol, as the protective effect of estrogen declines. This period is a critical window for lifestyle interventions to preserve endothelial function and reduce long-term cardiovascular risk.

Acute nighttime exposure to aircraft noise (approx. 60 dB peak) dose-dependently impairs endothelial function and increases plasma adrenaline levels in healthy adults, an effect mediated by oxidative stress.

If you live near an airport or noisy area, your body may be under chronic low-grade stress even if you sleep through the noise. This stress releases adrenaline and damages your blood vessel lining (endothelial function), increasing long-term cardiovascular risk. Protecting your sleep environment from noise is a valid preventive health measure, potentially as important as diet or exercise for vascular health.

Long-term energy balance is regulated by the reciprocal, antagonistic signals of glucocorticoids and insulin, where glucocorticoids stimulate food intake and insulin inhibits it, with the ratio of these hormones determining overall energy acquisition and deposition.

Your body's long-term weight regulation depends on the balance between stress hormones (glucocorticoids) and insulin. High stress can drive hunger, but this is modulated by insulin levels. Managing both stress and insulin sensitivity is key to regulating energy balance, rather than focusing on just one factor.